IgA nephropathy (IgAN) is characterized by the deposition of IgA1-containing immune complexes in the glomerular mesangium. The pathogenesis follows a 4-hit cascade: ...

Panelists discuss how patients with immunoglobulin A (IgA) nephropathy typically present with microscopic or gross hematuria, often during upper respiratory infections, along with variable proteinuria ...

Living with the rare condition of IgA nephropathy can feel lonely. Patient advocate Stuart Miller shares his treatment journey and how to stay connected with those who understand. Share on ...

Hansa Biopharma AB announced the appointment of Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.

Expanding Global Support: IgA Nephropathy Foundation Launches Go Global Network to Connect and Empower IgAN Patients Worldwide. By expanding our network to Canada, we are building a stronger, more ...

Sparsentan is an endothelin and angiotensin II receptor antagonist indicated to slow kidney function decline for adults with primary IgA nephropathy who are at risk for disease progression.

Vera Therapeutics (VERA) announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA ...